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Abstract
Background: Uptake of the human papillomavirus (HPV) vaccine in the UK is good, but there are pockets of the
community who remain unprotected. Immunisation teams usually require written parental consent for a girl to
receive the vaccine. Evidence suggests that uptake of the vaccine might be improved by promoting consent form
return (if returned, forms are likely to grant consent). Incentivising girls to return consent forms is a promising
approach to promoting consent form return. Before testing the efficacy of an incentive intervention in a
randomised controlled trial (RCT), we must first establish whether the RCT is feasible. In this randomised feasibility
study, we aim to establish the feasibility of conducting a cluster RCT of an adolescent incentive intervention to
increase uptake of HPV vaccination.
Methods: At least six schools will be randomised to either an incentive intervention arm or a standard invitation
arm. Girls in standard invitation arm schools will receive the usual HPV vaccine programme invitation materials. Girls
attending schools in the incentive intervention arm will receive the standard invitation and will also be told that
they will receive an incentive if they return their consent form (regardless of whether consent is granted or denied).
The incentive is being entered into a prize draw to win a retail voucher. Feasibility objectives include estimating the
schools’ and parents’ willingness to participate in the study and be randomised; response rates to questionnaires;
the extent of missing data; the girls’ and parents’ attitudes towards the incentive offered; school staff experiences of
participating, fidelity to the trial procedures, data on any unintended consequences and the possible mechanisms
of action, and proof-of-concept evidence of the effect of the intervention on consent form return rates and uptake
of the vaccine. Analysis of feasibility outcomes will primarily be descriptive. Consent form return rates and uptake of
the vaccine will be presented by trial arm without comparison.
Discussion: Incentivising HPV vaccine consent form return may promote HPV vaccine uptake. This study will
provide the evidence needed to establish whether testing this incentive intervention using a RCT design in the
future is feasible.
Trial registration: ISRCTN72136061
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Background
Human papillomavirus (HPV) is causally related to cancers
of the cervix uteri, penis, vulva, vagina, anus and orophar-
ynx. The development and worldwide implementation of
vaccines against HPV has the potential to substantially re-
duce the burden of HPV-related cancers. A quadrivalent
HPV vaccine is used in a UK HPV vaccination programme.
This vaccine provides protection against HPV types 16 and
18 that are known to cause up to 80% of HPV-related can-
cers (depending on cancer site) [1, 2], as well as against
HPV types 6 and 11 which cause most anogenital warts.
Vaccination works best if administered to HPV-naïve
individuals and in younger populations [3].
While uptake of the vaccine is high in England (89% of
12–13-year olds had at least one dose of the two-dose
series in 2014/2015 [4]), there are pockets of the popula-
tion who remain unvaccinated and there is huge vari-
ability in uptake between areas (from 68% in Kensington
and Chelsea to over 99% in the Isle of Wight). Research
exploring the association between socio-demographic
characteristics and uptake of HPV vaccination has sug-
gested that girls from some Black and Asian Minority
Ethnic (BAME) backgrounds are less likely to receive
HPV vaccination than girls from White British back-
grounds [5, 6]. This remains the case when controlling
for deprivation [7]. While high uptake in the UK should
offer herd protection to those who remain unvaccinated,
evidence of assortivity of sexual mixing exists [8, 9] (i.e.
partnerships are more likely within ethnic groups than
between them). As HPV is sexually transmitted, this
may mean there are population subgroups who do not
benefit from herd protection, thereby compounding dis-
ease inequalities. There is very little evidence about what
might work in a UK setting to increase uptake of HPV
vaccination [10, 11]. If an intervention is to be rolled out
nationally, it will need to be simple and easy to imple-
ment given the increasing workload of immunisation
teams (the child flu vaccine and a meningitis vaccine
protecting against types A, C, W and Y vaccine have re-
cently also be added to the immunisation schedule).
Informed consent is required for girls to receive the
HPV vaccine. While girls themselves may consent to
vaccination if they are deemed sufficiently competent, in
practice immunisation, teams usually require written
consent from their legal guardian [12]. In general, con-
sent forms are sent home from school with the girl and
are returned to the school in the same way. Consent
forms must be returned regardless of the parent’s deci-
sion (granting consent to vaccinate or not). Unpublished
data show that around 60% of consent forms are
returned without prompting and of the remaining 40%,
around half will consent to vaccination if followed up by
a (time consuming) telephone call from an immunisa-
tion nurse [13]. This suggests that there is a group of
parents who are open to providing consent, but who
may not do so without prompting. Interventions aimed
at promoting return of the consent form may, therefore,
increase vaccination uptake. Incentives may be a promis-
ing approach, particularly as incentives work best for
one-off behaviours [14–16], with the incentive being tar-
geted at consent form return and not vaccination
receipt. Various definitions of incentives have been used
previously [17, 18] and often to suit the topic of interest.
In the context of the present study, incentives will be
defined as financial and non-financial rewards or penal-
ties that may have a monetary or exchange value and are
contingent on the target behaviour.
Evidence for incentives in childhood immunisation
There is varying evidence from reviews about the use of fi-
nancial incentives to increase uptake of immunisation.
One systematic review [19] found that incentive interven-
tions result only in a small increase in uptake, and another
systematic review and meta-analysis reported that the
evidence is not strong for their use in low- and middle-
income countries [20]. A further systematic review found
few studies that had examined effectiveness of incentives
to increase uptake of preschool immunisations and only
one had reported on the cost and consequences of such
an intervention [21]. Contrarily, in a descriptive review of
the literature, Sutherland et al [16] concluded that there is
evidence that “modest incentives” increase uptake of vac-
cines and Dempsey et al. [22] argue that incentive inter-
ventions to increase vaccine uptake deserve further
investigation. Models of optimising vaccination uptake
have also recently been published that propose using in-
centives in this context (e.g. [23]). However, no trials have
considered incentives provided contingent on vaccination
consent form return1 and few studies have offered incen-
tives to the child/adolescent rather than the parents or
health professional. One experimental study found hepa-
titis B consent form return rates in Californian (USA)
schools to be higher where classes were offered an incen-
tive contingent on all consent forms being returned with
5 days of receipt [24] and as part of an Australian service
evaluation, schools were offered the opportunity to receive
an incentive if >90% of vaccination consent forms were
returned [25]. However the results for incentives were not
reported. In one UK trial, Mantzari et al. offered incen-
tives to older adolescent girls (aged 17–18) to receive the
HPV vaccine as part of a catch-up programme (delivered
through GPs and pharmacies) [26]. The tested incentive
comprised a total of £45 worth of Love2Shop retail
vouchers, which are redeemable at over 20,000 UK shops:
£20 for receiving doses one and three and £5 for receiving
the second dose. The incentive increased uptake of the
first and third doses. The offer of incentives did not affect
the quality of the girls’ decision to get the vaccine, as
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measured by the congruence between their attitudes to-
wards the vaccine and their vaccination status. A review
of methods to increase postal questionnaire response rates
found a two-fold improved response rate if monetary
incentives were offered [27], although this was not neces-
sarily among adolescents in a school-based setting.
Mechanisms of action
Incentives in this context may work because they in-
crease the perceived value of returning the consent form
(congruent with expectancy value and economic models
[28–33]). Incentives might also result in individuals allo-
cating cognitive capacity to efforts to receive the incen-
tive [34] or the immediate reward may enhance the
short-term benefits of returning the consent form [35].
Incentives may also function as a way of focusing an in-
dividual’s attention to something that they had previ-
ously not considered [36, 37]. Among adolescents, there
may also be a role of fear of missing out on something
one’s peers are experiencing [38] and some evidence
from neuroscience suggests that reward-related brain
activation is linked to improved memory, implying that
incentives make a behaviour more likely because the
individual remembers it [39].
Concerns about incentives
Use of incentives to improve health-related behaviours is
generally acceptable to many stakeholders [40, 41], but
varies depending on incentive type, its effectiveness, and
the nature of the health behaviour being targeted [42].
Sociodemographic variation in attitudes to incentives has
also been observed [17, 42], including ethnic variations,
which are likely due to the acceptability of the behaviour
the incentive is targeting, rather than the incentive itself
[17]. Cash incentives are seen as less acceptable [41], and
there is concern about the potential for abuse and fear of
being part of a “Nanny State”. There is also concern about
incentives undermining parental choice in immunisation
decisions [26, 43]; alternatively, girls “pestering” their par-
ents may encourage parents to engage with the decision.
We have conducted formative research with teachers
and girls, as well as consulting our study user groups com-
prising parents and immunisation nurses, to choose an
incentive that is acceptable to all vaccine stakeholders, as
well as likely to be sufficiently motivational to girls. It will
also be important to consider acceptability on a larger
scale, as well as monitoring unintended consequences.
The present study
It will be necessary to test the efficacy of the incentive
intervention in increasing HPV vaccination uptake using
a randomised controlled trial (RCT) design. Before this
is appropriate, we must establish whether the RCT is
feasible and establish parameters needed to design the
RCT. The proposed study is a randomised feasibility
study. Findings will inform the decision to conduct a fu-
ture RCT and will provide proof-of-concept evidence.
It is not our intention that incentives should be offered
to all girls as standard as part of the vaccination
programme (should incentives be found effective at
improving uptake), but that they be a tool that immun-
isation providers may use to improve uptake in schools
with particularly low coverage.
Aim
The aim of this study is to establish the feasibility of con-
ducting a cluster RCT of an adolescent incentive interven-
tion to increase uptake of HPV vaccination among girls.
Objectives
(1)Gain an estimate of school participation rates,
parent participation rates, response rates to a
parental questionnaire and response rates to girls’
questionnaire.
(2)Assess data quality and completeness.
(3)Determine the acceptability of the intervention and
acceptability and fidelity of the trial procedures.
(4)Estimate the cost per returned consent form and
cost per consent form that is agreeing to
vaccination.
(5)Identify longer term cost components that need to
be considered in a future economic evaluation.
(6)Obtain data on unintended consequences of the
intervention and mechanisms of action.
(7)Generate proof-of-concept evidence of the effect of
the intervention on HPV vaccination uptake.
(8)Generate proof-of-concept evidence of the effect of
the intervention on consent form return rates.
Methods/design
Trial design
The trial design is a two-arm cluster randomised feasi-
bility trial, with equal allocation to each arm (see Fig. 1).
Setting
The study will be conducted in the London boroughs of
Enfield, Lambeth and Southwark. In Enfield, uptake of
dose one of the two-dose HPV vaccine schedule is 75%
(the fourth lowest in the country; [4]) and around 49% of
residents are from a non-White British ethnic background
(predominantly other White2 and Black or Black British
Caribbean; [44]). Uptake of dose one in Lambeth is 82%
(average for London, but below average for England; [4])
and 60% of residents are from a non-White British ethnic
background, mainly Black African and Black Caribbean
[45]. Southwark has a similar dose one uptake rate to
Lambeth (83%; [4]) and around 42% of residents are from
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a non-White background, again, mainly Black African or
Black Caribbean [46].
Eligibility criteria
Secondary schools participating in the HPV immunisa-
tion programme in Enfield, Lambeth or Southwark are
eligible for the study. Within participating schools, ado-
lescent girls in school year eight are eligible to take part.
Feasibility data will also be collected from one parent of
each participating girl, school staff working in participat-
ing schools and HPV-related cancer prevention stake-
holders. There are no exclusion criteria.
Interventions
The feasibility trial has two arms: (1) standard invitation
and (2) incentive intervention plus standard invitation.
The standard invitation arm comprises adolescents be-
ing provided with an information leaflet about the HPV
vaccine and a consent form by their school, which they
are asked to give to their parents (delivered by hand)
and return to the school before a prescribed date.
Immunisation nurses may engage in additional promo-
tional activities with schools, and this information will
be collected. Participants in the incentive intervention
arm will receive the standard invitation. They will also
be advised by their school form tutor and in a letter
that they will be entered into a prize draw to win a £50
“Love2Shop” voucher if they return their consent form,
with a 1 in 10 chances of winning. It will be made clear
that they will be eligible for the incentive regardless of
whether consent is given. Schools in the intervention
arm will be asked to record the day the students are
Fig. 1 Trial flow diagram
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informed about the incentive and the name of the
teacher who did this.
The incentive aims to improve uptake among the 20%
of the eligible population who will consent to vaccination
if prompted to return their consent form; however, for
practical purposes, all girls in the intervention arm will be
eligible to receive the incentive if their consent form is
returned.
Outcomes
Feasibility outcomes collected prior to interventions be-
ing administered include the schools’ and parents’ will-
ingness to participate in the study and the schools’
willingness to be randomised (number of schools con-
tacted, number of those who express initial interest, and
number of those who participate). Feasibility outcomes
collected following interventions being administered
include response rates to questionnaires by the parents
and girls and data completeness regarding the
proportion of missing data, girls’ and parents’ socio-
demographic characteristics (including ethnicity, ascer-
tained through brief questionnaires, and index of
multiple deprivation (IMD) score, ascertained using the
girls’ postcodes provided by the schools). We will also
explore the girls’ and parents’ attitudes towards the in-
centive offered (assessed through brief questionnaires,
measure developed for this study) and school staff expe-
riences of participating (ascertained through brief inter-
views). Data on unintended consequences and
mechanisms of effect will be collected via questionnaires.
Unintended consequences include the girls’ perceptions
of why an incentive was offered, the girls’ attitudes
towards returning future consent forms (measures devel-
oped for this study) and whether parents made an in-
formed decision about vaccination (using questions
described in [26]). Mechanisms of effect include whether
the incentive increased motivation for returning the con-
sent form, improved memory for returning the form, in-
creased salience for returning the form, increased the
short-term benefits of returning the form, increased the
perceived value of returning the form and whether there
is a role for girls fearing missing out on the incentive
(using [38] and measures developed for this study). Trial
procedures will be documented by speaking to the
school staff about their fidelity to the intervention
(ascertained through brief interviews) and taking a de-
tailed description of immunisation processes performed
in each school (i.e. what additions to the standard invita-
tion were performed) by the immunisation teams and
school staff (ascertained through brief interviews with
school staff and email/telephone conversations with im-
munisation teams throughout the trial). Cost of the in-
centive intervention will be assessed by measuring (1)
the cost per returned consent form and (2) the cost per
form consenting to vaccination.
Proof of concept outcomes collected following the first
vaccination dose, including initiation of the vaccination
series, will be assessed by collecting data on whether
consent was given to vaccination reported by schools
and self-reported by parents in a brief questionnaire
(measure developed for this study). Consent form return
rates will be based on information collected by schools.
Study procedures
All secondary schools in Enfield, Lambeth and
Southwark will be approached. Legal guardians (usually
parents) from participating schools will be written to/
emailed explaining the study and those not wishing to
participate were asked to opt out to a school contact.
Schools randomised to the incentive intervention arm
will be sent the intervention letter to give to students
and teachers informed to tell students that they will be
eligible for the incentive if their consent form is
returned. At the same time, parents from schools in
both arms will be asked by the immunisation team to
consent to their daughter having the HPV vaccine as
part of the routine programme, via an invitation letter,
information leaflet and accompanying consent form.
These standard immunisation programme materials are
distributed to the girls by form tutors and their distribu-
tion/content is unaffected by the present study.
Following dose one of the vaccine being administered
to those girls with consent, the research team will give
the school administrative staff a list of unique anon-
ymised identifiers to assign to each participating girl.
The administrative team will add this list to an existing
dataset containing all vaccine-eligible girls and the fol-
lowing information: an IMD score for each girl (derived
from the girls’ postcodes), whether she returned a con-
sent form and whether consent to vaccination was given
on the consent form. Administrative staff will remove
the girls’ names from the dataset and provide this to the
researchers to take away from the school site.
Girls will be given a questionnaire to complete in the
week after vaccination day by their form tutor, as well as
a questionnaire pack to hand deliver to their parents.
The parents’ packs will include a FREEPOST return en-
velope to send the questionnaires directly to researchers.
Both questionnaires will be labelled with each girl’s
unique identifier. Parents with more than one daughter
in year eight will be asked to think of one child and re-
spond about that child when completing the ques-
tionnaire. Girls will complete the questionnaire during
a tutor group session. School staff will be invited to
participate in a brief interview in an email sent from
the research team via a member of the school admin-
istrative staff.
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All interviews will be conducted shortly after vaccin-
ation day, either in person or on the phone by a member
of the research team. Written/audio-recorded verbal in-
formed consent will be taken by a member of the
research team. They will be audio-recorded and
transcribed verbatim.
Sample size
This is a feasibility study and one of the outcomes will
be to assess the willingness of the schools to take part in
the study and to be randomised. We anticipate that at
least six schools will agree to participate in the study
based on our pilot work. On average, in participating
boroughs, there are approximately 100 girls in year eight
per school. With 600 girls, we will be able to estimate
the binary feasibility outcomes (participation rates, ques-
tionnaire response rates and acceptability of the trial
methods) with an unadjusted precision of the 95% confi-
dence intervals to at least ±5 percentage points assum-
ing the most statistically conservative scenario when the
proportion is 0.5.
Allocation
Blocked randomisation will be performed by the statis-
tical advisor using computer generated random
numbers. The statistical advisor will place pre-generated
randomisation lists on a list of participating schools
(with names concealed) and will send school allocation
to the study research assistant. The research assistant
will inform participating schools of their group
assignment.
Blinding
Once allocated (and information materials sent to
schools allocated to the incentive intervention arm),
group allocation will be kept separately from the main
dataset. Trial arms will be labelled “A” and “B” in the
dataset by the statistical advisor, who will keep the key
and the main analyst will be blind to the group alloca-
tion until analysis is complete. Participants will not be
blind to the group allocation.
Data management
Data will be input by a research assistant, with 10% of data
entered from questionnaires checked. If accuracy is
<100%, a further 10% of data entered will be checked, with
the process repeated until no errors are identified. Errors
will be corrected. No identifiable data will leave school
sites. Interview transcripts will be fully anonymised.
Statistical methods
As this is a feasibility study our primary focus will be on
assessing the outcomes regarding trial procedures, data
quality and estimates of design parameters. The analysis
for the feasibility outcomes will be primarily descriptive.
School characteristics will be presented by arm. Data are
available on participating and non-participating schools
regarding school size, whether schools are single sex/
mixed, and HPV vaccine uptake in the previous year.
Participating and non-participating schools will be com-
pared descriptively based on these factors to examine
how representative participating schools are of their re-
spective boroughs. Participant characteristics at baseline
will be presented overall, by arm and by school. We will
estimate and report on the proportion of schools
approached that participate, the proportion of parents
approached who opt out of the study, the proportion of
parents sent a questionnaire who return the question-
naire and the proportion of girls given a questionnaire
who complete the questionnaire.
We will estimate and report on the proportion of
missing data for consent form return rates, vaccination
consent, girls’ IMD score and all questionnaire items.
Acceptability of the incentive among girls and parents
will be assessed descriptively. Interviews will be analysed
descriptively to assess the range of opinions.
Parents’ mean informed decision-making scores will
be presented by cluster and by trial arm, as will the data
for other unintended consequences and mechanisms of
action. We will summarise by cluster and by trial arm,
the proportion of girls whose parents consent to the vac-
cine and the proportion of consent forms returned.
The trial will be reported according to the CONSORT
extension to cluster randomised trials, CONSORT exten-
sion to randomised pilot and feasibility trials and this proto-
col has been prepared using the SPIRIT guideline [47–49].
Missing data
The proportion of missing data for each variable col-
lected via questionnaire will be reported. In line with
Carpenter and Kenward [50], during a blind review of
the data, the lead analyst and the statistical advisor will
meet to decide upon the most appropriate missing data
model and will apply this prior to analysis.
Economic evaluation
Cost per returned consent form and cost per consent
form agreeing to vaccination will be defined as the total
unit cost of all consumables and incentive where rele-
vant, divided by the number of consent forms returned
or the number of consent forms returned that are agree-
ing to vaccination (following the method of Woodhall et
al. [51]).
Interviews will be conducted with HPV-related cancer
prevention stakeholders to identify the long-term cost
implications of the intervention, including the adminis-
tration of the incentive. This preparatory work will
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inform the economic analysis conducted as part of the
future RCT.
Monitoring
A trial management group comprising the study team
will meet at the beginning and end of the study and
throughout as needed. A data monitoring committee
was not deemed necessary for this feasibility study.
There will be no interim analyses or stopping guidelines.
All members of the study team will have access to the
final dataset. We do not anticipate any adverse events,
but unintended consequences of the intervention are be-
ing measured. Immunisation teams and school staff will
have a contact within the research team to report any
adverse events.
Deciding to proceed to a full trial
The decision to proceed to a definitive trial will be a
multifaceted one, based on the trial procedures being
acceptable to participants/stakeholders and feasible to
deliver and scale up.
Ethics and dissemination
Ethical approval has been received from the UCL
Research Ethics Committee (6615/002). Modifications to
this protocol will be communicated to relevant parties
by the principal investigator. Results will be published in
a peer review journal and presented at conferences.
Discussion
We have presented a protocol for a cluster randomised
feasibility study of an adolescent incentive intervention
to increase uptake of HPV vaccination among girls. The
study will help provide the answers to questions re-
quired to design any main trial and whether it is appro-
priate to proceed with a future trial.
We have previously achieved high response rates to
questionnaires completed by students in schools; however,
response rates to questionnaires posted to parents are
likely to be lower. Findings from this study will determine
whether this approach to data collection from parents is
likely to be successful in any main trial. We will also be
able to observe if certain questionnaire items are often
missing, suggesting that participants either did not under-
stand them or did not find them relevant, allowing us to
modify the questionnaires prior to any main trial.
Interviews with school staff may also help to explain any
missing data. Finally, we presently do not know if we will
obtain more complete data on vaccination status by asking
schools to record this data or by asking parents to report
their daughter’s vaccination status. Findings of this feasi-
bility study will suggest how best to collect data on vaccin-
ation status in any main trial.
The sample size is based on a conservative scenario
and if achieved will allow us to estimate binary feasibility
outcomes. For any main trial, a larger sample size will
likely be required; this will be determined following this
feasibility study. It is possible that schools participating
in the feasibility study will be the most engaged in re-
search. Further efforts may be required to recruit add-
itional schools for any main trial and may require input
from senior leadership to facilitate recruitment, such as
local authorities. We have engaged with local authorities
in the set-up of this feasibility study, so their input
should be possible in any main trial.
Uptake of the HPV vaccine among eligible 12–13-
year-old girls is sub-optimal in some populations. An in-
centive intervention to promote consent form return
may result in improved uptake. This cluster randomised
feasibility study will provide the evidence needed to
decide if a future RCT testing the efficacy of such an
intervention is feasible.
Trial status
Recruitment started on 1 July 2016 and ended on 15
December 2016.
Endnotes
1One trial protocol planned to offer the use of finan-
cial incentives to increase vaccination consent form
return rates as part of a multi-component intervention
(Skinner et al. 2015).
2White ethnicity, but not White British, White Irish or
White Gypsy or Irish traveller.
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